News
Wells Fargo Maintains Overweight on Ascendis Pharma, Raises Price Target to $260
15 Mar 24
News, Price Target, Analyst Ratings
Here's How Much $100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today
14 Mar 24
News, Trading Ideas
These Five Small-Cap Stocks Under The Radar Are Expected To Surge, Says Stock Researcher
3 Mar 24
News, Politics, Top Stories, Markets, General
$1000 Invested In This Stock 15 Years Ago Would Be Worth $45,000 Today
23 Feb 24
News, Trading Ideas
How Is The Market Feeling About Ascendis Pharma?
13 Feb 24
Short Sellers, Short Ideas, Trading Ideas
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $70,000 Today
8 Feb 24
News, Trading Ideas
Citigroup Maintains Buy on Ascendis Pharma, Raises Price Target to $182
8 Feb 24
News, Price Target, Analyst Ratings
Wedbush Maintains Outperform on Ascendis Pharma, Raises Price Target to $225
8 Feb 24
News, Price Target, Analyst Ratings
Ascendis Pharma Q4 2023 GAAP EPS $(1.66) Misses $(1.59) Estimate, Sales $148.22M Up From $23.37M YoY
7 Feb 24
Earnings, Earnings Misses, News
Earnings Scheduled For February 7, 2024
7 Feb 24
Earnings
Ascendis Pharma's Earnings: A Preview
6 Feb 24
Earnings
Cantor Fitzgerald Maintains Overweight on Ascendis Pharma, Raises Price Target to $173
6 Feb 24
News, Price Target, Analyst Ratings
$100 Invested In Ascendis Pharma 5 Years Ago Would Be Worth This Much Today
2 Feb 24
News, Trading Ideas
Er-Kim Announces Exclusive Distribution Agreement With Ascendis Pharma A/S To Commercialize 3 Endocrinology Disease Treatments Across Central & Eastern Europe And Turkey
8 Jan 24
Biotech, News, Global, General
Ascendis Pharma Introduces Vision 2030; Preliminary Unaudited December 31, 2023 Cash, Cash Equivalents, And Marketable Securities Of ~€400M; Full Year 2024 SKYTROFA Revenue Expected To Be €320M-€340M
7 Jan 24
News, Guidance
Specialised Therapeutics Signs Exclusive Agreement With Ascendis Pharma For Distribution And Commercialization Of Three Endocrinology Therapies In Australia And Select South-East Asia Countries
7 Jan 24
News, Contracts
Press releases
Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024
4 Mar 24
News, Press Releases
Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results
7 Feb 24
Earnings, Press Releases
Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024
31 Jan 24
Earnings, News, Press Releases
Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism
31 Jan 24
Health Care, Press Releases, General
Er-Kim Announces Exclusive Distribution Agreement with Ascendis Pharma A/S to Commercialize 3 Endocrinology Disease Treatments Across Central & Eastern Europe and Turkey
8 Jan 24
Health Care, Press Releases
Vector Pharma FZCO Announce Exclusive Distribution Agreement with Ascendis Pharma A/S for Skytrofa (lonapegsomatropin) and Yorvipath (palopegteriparatide) in Gulf Cooperation Council Countries
8 Jan 24
Health Care, Press Releases
Ascendis Pharma Introduces Vision 2030
7 Jan 24
Press Releases, General
Specialised Therapeutics signs exclusive agreement with Ascendis Pharma A/S for distribution and commercialisation of three endocrinology therapies in Australia and select South-East Asia countries
7 Jan 24
Press Releases